Earnings summaries and quarterly performance for Cingulate.
Executive leadership at Cingulate.
Board of directors at Cingulate.
Research analysts covering Cingulate.
Recent press releases and 8-K filings for CING.
Cingulate Inc. announces private placement of securities
CING
Convertible Preferred Issuance
- Cingulate Inc. entered into a Securities Purchase Agreement on January 27, 2026, for a private placement of securities.
- The private placement involves the issuance of 2,147,471 shares of common stock, 973 shares of Series A convertible preferred stock, and warrants to purchase 1,868,482 shares of common stock.
- The transaction generated aggregate gross proceeds of approximately $12,000,000 at a price of $5.14 per share of common stock (including $0.10 per Warrant Share).
- Cingulate Inc. intends to use the net proceeds from the private placement for working capital and general corporate purposes.
- The issuance of the preferred stock and warrants is contingent upon Stockholder Approval, for which the company will file a proxy statement and hold a meeting.
Jan 28, 2026, 9:10 PM
Cingulate Reports Q3 2025 Results, CTx-1301 NDA Acceptance, and Financing
CING
Earnings
New Projects/Investments
Debt Issuance
- Cingulate Inc. reported a net loss of $7.3 million for the third quarter ended September 30, 2025.
- The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for CTx-1301, setting a PDUFA target action date of May 31, 2026.
- The company appointed Bryan Downey as Chief Commercial Officer and completed a $6 million financing transaction to strengthen its balance sheet.
- As of September 30, 2025, Cingulate had $6.1 million in cash and cash equivalents and anticipates needing to raise approximately $7.0 million of additional capital to fund commercialization efforts through the PDUFA date.
Nov 13, 2025, 1:15 PM
Cingulate Reports Q3 2025 Financial Results, FDA Accepts CTx-1301 NDA, and Completes $6 Million Financing
CING
Earnings
Product Launch
Debt Issuance
- Cingulate reported a net loss of $7.3 million for the third quarter ended September 30, 2025, with $6.1 million in cash and cash equivalents and $1.6 million in working capital as of that date.
- In October 2025, the U.S. Food and Drug Administration (FDA) accepted Cingulate's New Drug Application (NDA) for CTx-1301, assigning a PDUFA target action date of May 31, 2026.
- On November 3, 2025, Cingulate appointed Bryan Downey as Chief Commercial Officer and completed a $6 million financing transaction, structured as a non-convertible, unsecured promissory note, to strengthen its balance sheet for potential commercialization.
- The company expects its current cash to satisfy capital needs into the second quarter of 2026 and will need to raise approximately $7.0 million of additional capital to advance commercialization efforts through the PDUFA date.
Nov 13, 2025, 1:00 PM
Cingulate's New Drug Application for CTx-1301 in ADHD Accepted by FDA
CING
Product Launch
New Projects/Investments
- Cingulate Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for CTx-1301, a lead candidate for treating Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adults.
- The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026, for the review of CTx-1301.
- CTx-1301 is a once-daily Precision Timed Release™ (PTR™) stimulant, and its NDA was accepted under the FDA's 505(b)(2) regulatory pathway.
- This acceptance is a significant regulatory milestone, positioning Cingulate to potentially transition from a development-stage to a commercial-stage company in 2026, pending FDA approval.
Oct 14, 2025, 12:15 PM
Cingulate Announces FDA Acceptance of CTx-1301 NDA with May 2026 PDUFA Date
CING
Product Launch
New Projects/Investments
- Cingulate Inc. announced that the FDA has accepted for review its New Drug Application (NDA) for CTx-1301 (dexmethylphenidate), its lead candidate for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adults.
- The NDA was accepted under the FDA’s 505(b)(2) regulatory pathway.
- The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026.
- CTx-1301 is a once-daily Precision Timed Release™ (PTR™) stimulant designed for rapid onset and entire active-day duration, which demonstrated improved ADHD symptoms and sustained efficacy in adult and pediatric Phase 3 clinical trials.
- This milestone positions Cingulate to potentially transition to a commercial-stage company in 2026, pending FDA approval, and the company is advancing commercial readiness activities.
Oct 14, 2025, 12:13 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more